Chief Science Officer
Dr. Khursheed Anwer to
D
eliver
V
irtual
P
resentation on Celsion’s
O
ngoing
W
ork with DNA-based
V
accines
LAWRENCEVILLE, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN),
a clinical-stage development company focused on DNA mediated immunotherapy and next-generation nucleic vaccines, announces that Khursheed Anwer, Ph.D., executive vice president and chief science officer, will be presenting at the International Vaccines Congress being held virtually October 18-20, 2021. Dr. Anwer’s presentation is titled “Immunogenicity of DNA Vaccines based on Multicistronic Vectors and Synthetic DNA Delivery Systems.” The date and time of the presentation will be announced following publication of the conference agenda.
Dr. Anwer will be discussing ongoing proof-of-concept studies in SARS-CoV-2 with the Company’s DNA-based vaccine approach utilizing its PLACCINE platform. PLACCINE, Celsion’s proprietary design for DNA vectors, encompasses molecular elements designed to improve the immune response by targeting multiple antigens of a pathogen or multiple mutants of the same antigen. Dr. Anwer will review the PLACCINE technology and the production of a family of DNA vaccine vectors expressing one or more SARS-CoV-2 surface antigens as a proof-of-concept target, verified vector composition and demonstrated expression of the encoded genes.
“The International Vaccines Congress is an ideal forum to discuss our ongoing work with unique approaches to DNA-based vaccines.We view their acceptance of Dr. Anwer’s abstract as support for our scientific rigor and the promise of our work,” said Michael H. Tardugno, chairman, president and chief executive officer of Celsion. “We previously reported that immunization of Balb-C mice with a plasmid expressing the Spike protein of SARS-CoV-2 resulted in the production of IgG antibodies with evidence of viral neutralization and cytotoxic T-cell response specific to the antigen. We look forward to reporting this and additional data as we continue to make excellent progress with our PLACCINE platform.”
About the PLACCINE
P
latform
PLACCINE is Celsion’s proprietary plasmid and DNA delivery technology and the subject of a provisional patent application that covers a broad range of next-generation DNA vaccines. An adaptation of the Company’s TheraPlas technology, PLACCINE is a DNA vaccine technology platform characterized by a single plasmid DNA with multiple coding regions. The plasmid vector is designed to express multiple pathogen antigens along with a potent immune modifier. It is delivered via a synthetic delivery system and has the potential to be easily modified to create vaccines against a multitude of infectious diseases, addressing:
-
Viral Mutations
: PLACCINE may offer broad-spectrum and mutational resistance (variants) by targeting multiple antigens on a single plasmid vector. -
Enhanced Efficacy
: The potent immune modifiers such as cytokines and chemokines may improve humoral and cellular responses to viral antigens and can be incorporated in the plasmid. -
Durable Efficacy
: PLACCINE delivers a DNA plasmid-based antigen that can result in durable antigen exposure and a robust vaccine response to viral antigens. -
Storage & Distribution
: PLACCINE allows for stability that is compatible with manageable vaccine storage and distribution. -
Dosing & Administration
: PLACCINE is a synthetic delivery system that should require a simple injection that does not require viruses or special equipment to deliver its payload.
About Celsion
Corporation
Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies, DNA-based therapies and directed chemotherapies through clinical trials and eventual commercialization. The company’s product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection. For more information on Celsion, visit
www.celsion.com
.
Forward-looking Statements
Forward-looking
statements
in
this
news
release
are
made
pursuant
to
the
“safe
harbor”
provisions
of
the
Private
Securities
Litigation
Reform
Act
of 1995.
These
statements
are
based
upon
current
beliefs,
expectation,
and
assumptions
and
include
statements
regarding
the
platform
having
the
potential
to
provide
broad
protection
against
coronavirus
disease
2019
(COVID-19),
and
possible
future
mutations
of
SARS-CoV-2
or
other
coronaviruses.
These
statements
are
subject
to
a
number
of
risks
and
uncertainties,
many
of
which
are
difficult
to
predict,
including
the
ability
of
the
Company’s
platform
to
provide
broad
protection
against
COVID-19,
and
possible
future
mutations
of
SARS-CoV-2
or
other
coronaviruses,
the
issuance
of
a
patent
to
the
Company
for
use
of
its
technology
platform
for
treating
or
preventing
infection
with
the
SARS-CoV-2
virus
that
causes
COVID-19,
unforeseen
changes
in
the
course
of
research
and
development
activities
and
in
clinical
trials;
the
uncertainties
of
and
difficulties
in
analyzing
interim
clinical
data,
particularly
in
small
subgroups
that
are
not
statistically
significant;
FDA
and
regulatory
uncertainties
and
risks;
the
significant
expense,
time
and
risk
of
failure
of
conducting
clinical
trials;
the
need
for
Celsion
to
evaluate
its
future
development
plans;
possible acquisitions
or
licenses
of
other
technologies,
assets
or
businesses;
possible
actions
by
customers,
suppliers,
competitors
or
regulatory
authorities;
and
other
risks
detailed
from
time
to
time
in
the
Celsion’s
periodic
filings
with
the
Securities
and
Exchange
Commission.
Celsion
assumes
no
obligation to update
or supplement
forward-looking
statements that
become untrue because
of
subsequent events,
new
information
or
otherwise.
CONTACTS:
Celsion Corporation
Jeffrey W. Church
Executive Vice President and CFO
609-482-2455
[email protected]
LHA Investor Relations
Kim Sutton Golodetz 212-838-3777
[email protected]
# # #
